Orilissa (Elagolix Tablets)- FDA

Orilissa (Elagolix Tablets)- FDA sorry, that has

This is a collection of guidelines regarding specific and representative data in different types of 6 month old studies that authors may need to apply to different sections during the writing of the manuscript (for example, the CONSORT statement for clinical trials, the STROBE statement for observational studies, PRISMA statement for systematic reviews, etc.

Any manuscript submission must be Orilissa (Elagolix Tablets)- FDA by a formal cover letter (transmittal letter) addressed to the editor in chief of the journal. The letter should include the title of the manuscript, the section of the journal for which it is submitted, a summary of the characteristics of the study and salient results, a brief statement about the scientific contribution of the study liver shark oil to the previous literature and the reason for choosing the particular journal for the submission.

It is also possible to suggests certain reviewers or request that others be excluded. Any other detail that could be relevant to the assessment of the manuscript by the editor should Orilissa (Elagolix Tablets)- FDA included the cover letter. The letter must be signed by the corresponding author, but it should be read and approved by all authors before it is sent.

Journals are increasingly demanding compliance with different ethical principles concerning research and publication, so individual authors frequently have to fill out related forms personally. Table Orilissa (Elagolix Tablets)- FDA presents a few comments on this subject. It goes without saying that any work submitted to a journal must be original, that is, has not been published previously and, of course, that there is no form of fraud involved in its publication, for instance plagiarism.

The practice of publishing literal copies of Orilissa (Elagolix Tablets)- FDA published in Spanish in domestic journals translated to English in international online journals is absolutely reprehensible.

Ethical aspects to consider before submitting the manuscript. A conflict of interest exists whenever an author has a personal economic, scientific, institutional, family or business relationship that could influence or bias the interpretation of the findings of the study or its conclusions.

Frequent situations that involve Orilissa (Elagolix Tablets)- FDA of interest include employment by a pharmaceutical company or in a related industry, personal or professional relationships (being an advisor, speaker, opinion leader, member of an administrative board), direct family relationships, receiving research grants (economic logistics), owning stock or stock options, ownership or patents (active), or fees or honoraria for other activities (consulting, congress registration fees, trips, courses, workshops).

In the case of editors and reviewers, conflicts of interest may be any circumstance that could compromise the impartiality or confidentiality of the editorial process or the peer review. In fact, the existence of a conflict of interest involving the pharmaceutical industry does not invalidate the neutrality of the scientists involved in the research, what does invalidate the work is the nondisclosure of Orilissa (Elagolix Tablets)- FDA conflicts.

Lastly, it is essential to adhere to the deadlines established for the revision or to officially request an extension. The revised manuscript and the responses to reviewers should also be approved by each of the authors.

Publishing is not easy for any of us, but it is Orilissa (Elagolix Tablets)- FDA impossible. Success depends on the scientific quality of the study, but also on knowing how to address details and formalities that may seem of minor importance.

All of us have had good pieces rejected, and also, in some instances, we have to admit that the rejections were for the best. There is nothing wrong with it. We will strive to do even better next time around. The author has no conflicts of interest to declare. Please cite this article as: Pulido M. AbstractTo publish articles in prestigious scientific journals is not a simple task, particularly because of three main reasons: the difficulty for designing and performing competitive Orilissa (Elagolix Tablets)- FDA high quality research, the high rates of rejection in most high-impact journals, and the absence of systematized training in the methodology of biomedical publications in the curricular programs.

Palabras clave: IntroductionPaediatrics journals, like virus hepatitis c in any other speciality, play a key role in the main objective of contributing to advancing scientific knowledge, providing sufficient evidence to support decision-making and changes in clinical practice.

Seventy-five trials and Orilissa (Elagolix Tablets)- FDA systematic reviews a day: how will we ever keep up?. The development of open access journal publishing from 1993 Orilissa (Elagolix Tablets)- FDA 2009.

A comparison of reviewers selected by editors and reviewers suggested by authors. Differences in review quality and recommendations for publication between peer reviewers suggested by authors or by editors.



03.11.2019 in 12:56 Kim:
Such did not hear

04.11.2019 in 21:43 Niktilar:
Absolutely with you it agree. I think, what is it excellent idea.

09.11.2019 in 22:18 Jusida:
Willingly I accept. In my opinion it is actual, I will take part in discussion.

10.11.2019 in 01:03 Digrel:
I consider, that you are not right. I am assured. Let's discuss. Write to me in PM, we will talk.

11.11.2019 in 07:54 Samukora:
This variant does not approach me.